Olympus Growth Fund VII, L.P. managed by Olympus Partners entered into a definitive agreement to acquire Soliant Health, Inc. from Adecco Group AG (SWX:ADEN) for approximately $610 million on November 5, 2019. The consideration will be paid in cash. Upon closing, Soliant Health will join Vaco, acquired by Olympus Partners in 2017. In the 12 months ended June 30, 2019, Soliant generated revenues of $344 million and EBITDA of approximately $54 million. Hart-Scott-Rodino filings have been made for the transaction and is subject to regulatory and other customary closing conditions. As of November 22, 2019, FTC granted the early termination notice. The transaction is expected to be completed by first quarter of 2020. The divestment is expected to result in a gain on sale for Adecco Group to be recognized upon closing and it will provide an update on the use of proceeds with its fourth-quarter results in February 2020. J.P. Morgan Securities LLC acted as financial advisor to Adecco Group. Benjamin Clinger and Adam Wexner from Kirkland & Ellis LLP acted as legal advisors for Olympus Partners. Jay Schwartz, Eric Mandus, Julie Sebastian, Nicholas Rueter, Tom Hong, Joseph Mandarino and Brandon Sherlinski of Smith, Gambrell & Russell, LLP acted as legal advisors for Adecco Group. Olympus Growth Fund VII, L.P. managed by Olympus Partners completed the acquisition of Soliant Health, Inc. from Adecco Group AG (SWX:ADEN) on January 3, 2020. As of January 3, 2020, the transaction received all the regulatory approvals. As of January 16, 2020, Audax Private Debt has provided a senior secured credit facility to support the acquisition of Soliant Health.